Pfizer/BioNTech on ‘Encouraging’ Covid Booster Data

Pfizer and BioNTech have announced results showing that their current authorized bivalent booster vaccine provides a greater increase in neutralizing antibody titers than their original Covid-19 vaccine against emerging Omicron sublineages. “Based on these findings, the Omicron BA.4/BA.5-adapted bivalent booster may help to provide improved protection against Covid-19 due to Omicron BA.4 and BA.5 sublineages as well as new sublineages that continue to increase in prevalence,” the companies say.

They say that the latest results are similar to recent clinical data showing the Omicron BA.4/BA.5-adapted bivalent booster vaccine provides a “13-fold increase in BA.4/BA.5 neutralizing titers from pre-booster levels in individuals 55 years and older, resulting in a 4-fold higher BA.4/BA.5-response than the companies’ original Covid-19 vaccine.”